Geode Capital Management LLC Sells 3,088 Shares of Fresenius Medical Care AG (NYSE:FMS)

Geode Capital Management LLC lessened its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 3.3% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 90,750 shares of the company’s stock after selling 3,088 shares during the period. Geode Capital Management LLC’s holdings in Fresenius Medical Care were worth $1,933,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Fresenius Medical Care by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock worth $345,000 after purchasing an additional 1,128 shares in the last quarter. Caprock Group LLC acquired a new position in Fresenius Medical Care during the second quarter worth $208,000. American Century Companies Inc. raised its position in Fresenius Medical Care by 29.3% during the second quarter. American Century Companies Inc. now owns 24,046 shares of the company’s stock worth $459,000 after acquiring an additional 5,445 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Fresenius Medical Care by 14.4% during the second quarter. Dimensional Fund Advisors LP now owns 12,539 shares of the company’s stock worth $239,000 after acquiring an additional 1,576 shares in the last quarter. Finally, Wulff Hansen & CO. lifted its stake in Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after acquiring an additional 325,439 shares during the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Price Performance

Fresenius Medical Care stock opened at $22.40 on Thursday. The company has a market capitalization of $13.14 billion, a price-to-earnings ratio of 18.51, a PEG ratio of 0.95 and a beta of 0.92. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. Fresenius Medical Care AG has a 12 month low of $17.93 and a 12 month high of $24.31. The stock’s 50 day moving average is $22.39 and its 200-day moving average is $20.73.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on FMS shares. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective on the stock. StockNews.com initiated coverage on Fresenius Medical Care in a research report on Friday, January 3rd. They set a “strong-buy” rating on the stock. Truist Financial upped their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday. Finally, Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.